Clinical study of flupentixol and melitroxine in the treatment of refractory cough

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035304

Enrollment

Unknown

Registered

2020-08-07

Start date

2021-01-01

Completion date

Unknown

Last updated

2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory cough

Interventions

experimental group:Flupenthixol and Meritroxine

control group:Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 18 years old = 3; 5. Subjects have a clear understanding of the purpose of the research and are willing and able to complete the research in compliance with the requirements, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Smoking or quitting smoking for <= 2 years; 3. A history of new respiratory tract infection within 8 weeks; 4. The treatment of flupentixol and melitroxine is contraindication or history of allergy; 5. Active liver and kidney disease.

Design outcomes

Primary

Measure	Time frame
The success rate of flupentixol and melitrazin in the treatment of patients with refractory cough;	—

Secondary

Measure	Time frame
Cough symptom score;LCQ;HARQ;NLHQ;Capsaicine cough threshold;GAD-7;HAMA;PHQ-9;HAMD;The incidence of side effects;	—

Countries

China

Contacts

Public ContactZhongmin Qiu

Shanghai Tongji Hospital

qiuzhongmin@tongji.edu.cn+86 13671892140

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026